Su_manr DNA adduct levels were measured with atomic spectroscopy in white blood cells (WBCs) from patients with sold tumours who were treated with six weekly courses of cisplatin. In 21 patients (I) the WBCs were collected after thawing frozen whole-blood samples according to a previously described method. In 32 other patients (II) WBCs were collected immediately after blood sample collection. The two methods for WBC collection were also compared in vitro. The maximal DNA adduct levels in vivo after the first course were in I 2.48 ± 1.14 and in 11 1.28 ± 0.40 pg of platinum per fig of DNA (P<0.0001). The DNA 'repair' in the first course (DNA adduct level at the end of the infusion minus the level 15 h post infusion) was in I 40% ± 29% and in 11 18% ± 29% (P = 0.009). These differences were consistent in all measured courses. In vitro, the DNA adduct levels in the freshly prepared WBCs were significantly lower at 0. 1 and 4. but not 24 h, after start of the incubation with cisplatin than in the WBCs collected after freezing and thawing the blood sample. The same experiment with carboplatin in vitro also resulted in significantly lower adducts in freshly isolated WBCs. The higher DNA adduct levels and DNA 'repair' in I are caused by remaining unbound cisplatin in the sample tubes, which can form DNA adducts ex vivo. The same results in vivo can be anticipated when carboplatin is used.
cis-Diamminedichloroplatinum II (cisplatin) is one of the most potent anti-cancer agents with substantial clinical activity against testicular cancer, ovarian cancer, head and neck (H/N) cancer and other tumours (Loehrer and Einhorn. 1984; Reed et al., 1987) . The anti-tumour activity of cisplatin correlates with its interaction with DNA, resulting in a limited number of inter-and intrastrand cross-links ('adducts') (Fichtinger-Schepman et al., 1990) . In previous studies wide inter-patient variation was established in the DNA adduct kinetics in white blood cells (WBCs), which was monitored with different enzyme-linked immunosorbent assays (ELISAs) as well as with atomic spectroscopy (AAS) (Reed et al., 1987a (Reed et al., , 1988a (Reed et al., , 1990 Fichtinger-Schepman et al.. 1987 , 1989a Parker et al., 1991) . The DNA adduct levels in WBCs correlated with the clinical response in testicular, ovarian and other cancer patients who were treated with cisplatin, however substantial overlap in DNA adduct levels was observed between responding and non-responding patients (Reed et al., 1987 (Reed et al., , 1988a . It is important to realise that quantitation of the DNA-adduct kinetics with different published ELISA and AAS methods (Fichtinger-Schepman et al., 1987 Reed et al., 1987a Reed et al., ,b 1988a Parker et al., 1991; Poirier et al., 1993) and different sample preparation techniques (Reed et al., 1987; Fichtinger-Schepman et al., 1987 ) resulted in > 10-fold differences in the DNA adduct levels and shape of the DNA adduct-time curve in patients treated with the same dose range of cisplatin. Hence crossvalidation of the published methods is very much needed.
We monitored the DNA adduct kinetics in WBCs from patients who were treated with six weekly courses of cisplatin. In the first group of patients we applied the protocol for sample preparation which is described by FichtingerSchepman et al. (1987, 1990) and which is also applied in other ongoing studies. During the study we modified the sample preparation procedure because we suspected that application of the previously published method resulted in overestimation of the DNA adduct levels shortly postinfusion and of the DNA repair. We describe the two procedures and the influence on the quantitation of the DNA adduct levels in vivo. We measured the DNA adduct-time curve in WBCs from patients to determine the time point at which the DNA adduct level reaches its maximal value. Furthermore, we simulated the two sample preparation procedures in vitro using cisplatin as well as carboplatin as model substrates to identify clearly the mechanism behind the difference in the two assays. Blood sanple collection In all patients samples of 20 ml of hepanrnised blood were drawn during the first, third and sixth course: before cisplatin infusion (baseline), after the end of the infusion and 15 h after the end of the infusion. In the first group of 21 patients (I) the second blood sample was taken at the end of the infusion, whereas in the second group of 32 patients (II) the sample was taken 60 min after the end of the infusion.
The whole-blood samples collected in group I were frozen immediately at -80'C until analysis. The whole-blood samples which were drawn from patients in group II were centrifuged immediately for collection of the WBC.
In 7 of the 32 patients in group II, more blood samples were collected for measurement of the DNA adduct levels. The sampling times in these patients were at baseline and at 0, 1, 2, 5 and 15h after the end of the 3h infusion of cisplatin. (1987) . Briefly: two portions of 10 ml of frozen whole blood are thawed and a volume of 30 ml of the lysis buffer is added to each of the portions. The rest of the procedure is the same as outlined above.
In vitro simulation of the two sample preparation methods A volume of 120 ml of whole blood was taken from four healthy volunteers. The whole blood was incubated with cisplatin (approximately 10 jig ml-1) at 37C in a humidified atmosphere of 5% carbon dioxide in air. At 0 (i.e. no incubation after addition of cisplatin). 1. 4 and 24 h after start of the incubation 30 ml of blood was taken and divided into two portions. In one portion the WBCs were collected and frozen immediately as described above. The second wholeblood portion was frozem immediately at -80'C. On a second occasion a volume of 30 ml of whole blood was collected from the same volunteers and incubated with cisplatin (same concentration of 10 gg ml-'). After 0 h of incubation the sample was divided into two portions: one for immediate collection of WBCs before storage at -80'C and the other for immediate storage at -80'C. These samples were stored at 80'C for only 20 mn then thawed and processed immediately afterwards. All other samples were stored at -80'C for 2 weeks. Subsequently. the WBCs were collected as outlined above. The DNA adduct levels of these samples were measured on the same day.
In another experiment a volume of 120 ml was collected from the four volunteers for the incubation experiment with carboplatin. The incubation concentration was 200 tig ml-'.
The incubation conditions were the same as in the experiment with cisplatin. The storage of duplicate samples for only 20 min at -80'C was not repeated with carboplatin.
To study the influence of addition of RNAse on the DNA yield and DNA adduct level, a separate experiment was carried out. A volume of 20 ml of heparinised whole blood was drawn from four other subjects. The WBCs were collected immediately and the DNA isolated as outlined. The DNA was dissolved in a volume of 2 ml of a Tris-EDTA buffer (10 nmol Tnrs. 2 mmol EDTA. pH 7.35) and divided into two equal portions. RNAse, which was heated before use for 5 min at 80'C. was added to one of the portions to a final concentration of 100 yig ml-' and incubated for 2 h at 37C. The other portion served as control. After 2 h the DNA was isolated again as outlined by addition of 0.33 ml of saturated sodium chlonrde (6 M) and subsequently precipitated with absolute ethanol. The DNA content and the DNA adduct levels were compared with the control samples. Each experiment was carred out using four samples in duplicate.
Statistical analysis
The unpaired Student t-test was used to descnrbe differences between the DNA adduct levels in vivo in patient groups I and II. The paired Student t-test was used to describe differences between the DNA adduct levels in vitro. The paired Student t-test was also used to describe differences between the DNA adduct levels in vivo measured at the end of the infusion of cisplatin and at 1 h post infusion in the outlined group of seven patients. Figure 3) . The DNA adduct levels in the WBCs which were collected after thawing frozen whole-blood samples were higher than in the WBCs which were collected immediately after blood sample collection. The DNA adduct level at 0 h after start of the incubation was 494% higher (P<0.0001), at 1 h was 110% higher (P< 0.0001), at 4h 19% (P=0.02) and at 24h only 6% (not significant). The DNA adduct levels in the samples which were stored at -80C for only 20 min were not significantly different from the samples which were stored for 2 weeks at -80°C. After incubation with carboplatin, the DNA adduct levels in WBCs collected after thawing the frozen whole-blood sample were significantly higher at 0, 1, 4 and 24 h of incubation compared with the freshly collected WBCs (Figure 4) . At Oh the DNA adduct level was 335% higher (P =0.001), at 1 h 168% (P= 0.002), at 4h 121% (P= 0.008) and at 24h 11% (P = 0.03) higher than in the freshly isolated WBCs. (Reed et al., 1987 (Reed et al., , 1988a (Reed et al., , 1990 Fichtinger-Schepman et al., 1989a Parker et al., 1991; Poirier et al., 1993) . In clinical trials DNA adduct kinetics has been measured in WBCs because of the limited access to tumour tissue. The mean level of DNA adduct formation in responding patients was significantly higher than in nonresponding patients, although the range of the data showed an almost complete overlap (Reed et al., 1987a (Reed et al., , 1988a . In a recently published study in patients with germ cell tumours however, no significant positive correlation was observed between DNA adduct formation in WBCs and favourable clinical response (Motzer et al., 1994 were treated with six weekly courses of high-dose cisplatin of 70-80 mg m2. In the first 21 patients the DNA adduct levels were measured in WBCs, which were collected after thawing frozen whole-blood samples drawn at the end of the infusion of cisplatin according to the method previously described (Fichtinger-Schepman et al., 1987 . The method of WBC collection was modified because we suspected an overestimation of the DNA adduct levels shortly post infusion and an overestimation of the DNA repair. In addition, we wanted to determine the time point after infusion of cisplatin at which the DNA adduct level in WBCs is at its maximum value. In the modified procedure WBC& were iso- lated im iately after collection of the blood sample of the patient The differences in DNA adduct levels betwen the two methods are illustrated in Figure 1 . The DNA adduct levels immediately post infusion in the patients denoted as group I are sgnificntly higher than in the paients of group H. The variability in the DNA levels in group I was also higher than in group H, which is illustated by the higher coefficients of variation.
There was a difference in sampling time of nearly 60 min between groups I and H. Measurement of the DNA adduct levels at 1 h post infusion in seven patients of group H revealed that the levels were 40% higher than at the end of the infusion. Hence, the difference in the sampling time cannot explain the observed difference. In addition, it seems to be favourable to measure DNA adduct levels in WBCs at 1 h post infusion to obtain the best estimate of the maximal DNA adduct level. The half-life of unbound cisplatin in vivo is approximately 30 min (Vermorken et al., 1982) , which indicates that during the first hour post infusion WBCs are still exposed to significant concentrations of active casplatin. This appears to be the most reasonable explanation for the increased DNA adduct levels at 1 h post infusion compared with the level at the end of the infusion.
The difference between the DNA adduct levels groups I and II can be explained by the presence of unbound dsplatin in the blood sample tube, which can form DNA adducts ex vivo. As a consequence of the short half-life of unbound cisplatin, the concentration of unbound splatin is almost zero 15 h post infusion. If WBCs are isolated imediately after collection of the blood sample, then the redistribution of isplatin and binding to the DNA in WBCs ex vivo can be prevented. The sharp decine in the DNA adduct level between the end of the infusion and some time the next morning (approximately 15 h later) has been interpreted previously as DNA repair (Fichtinger-Schepman et al., 1987 ). The DNA repair in group H during the first course was on average more than 50% lower than in the patients of group I (Table I ).
The differences between the DNA adduct levels at 15 h post infusion in groups I and H were much smaller. The difference was signnt during the first course, not significant during the third and marginaLly significnt during the sixth course. This is in line with the almost undetectable concentration of unbound cisplatin in patients at this time point. It cannot be excluded that unbalanced patient selection and variation in the dosage of cisplatin contributed to the observed differences between groups I and H. The mean and s.d. of the administered dose of csplatin in the two treatment groups were not significntly different, however the pharmacokinetics of unbound isplatin may have been different. Variation in the pharmacokinetics may result in differences in the DNA adduct levels between the patient groups, because in a previous study a linear relationship was observed between the exposure to unbound cisplatin and the level of the DNA adduct formation in WBCs (Ma et al., 1994b) .
The two methods of WBC collection were simulated in vitro to exclude further the contribution of differences in the sampling and pharmacokinetics of cisplatin. The DNA adduct level in WBCs of whole blood incubated in vitro with cisplatin was 494% higher after 0 h of incubation and 110% higher after 1 h of incubation (Figure 3) . After 4 h the difference was reduced to 19%, whereas after 24 h the difference was only 6% and no longer significant. The concentrationtime curve of asplatin in vitro (Figure 5) vivo and the presence of unbound carboplatin in the sample tubes confirms the mechanism of the described phenomenon.
The DNA adduct levels in vitro after incubation with carboplatin are significntly higher even after 24 h of incubation. The disappearance half-life of carboplatin in vitro, however, is much longer than of cisplatin, and after 24 h the concentration of unbound carboplatin is still 54% of the starting level. This explains the significnt difference in the DNA adduct levels between the two sample handling methods at this late time point.
WBC coliection from frozen whole-blood samples is applied in ongoing clnical studies, for example in one crried out within the framework of the World Health Organization. The aim of these studies is to establish the relationship between DNA adduct kinetics and the tumour response in patients with solid tumours. It should be realise that the WBC collection method used in these studies will result in overestimation of DNA adduct levels and DNA 'repair'.
hi addition, WBCs should be collected imm atey after the blood sample has been drawn to further reduce variation in the DNA adduct measurement. Standardisation of this procedure is recommended. It is of interest to reveal any contribution of method variation to the inter-patient variability in DNA adduct levels in WBCs. It may reduce the observed overlap in DNA adduct levels between responders and non-responders to isplatin chemotherapy. Also, after administration of carboplatin, WBCs should be isolated immdi;ately if the blood sample is drawn during the time Period that unbound carboplatin in plasma can be anticipated.
We have quantitated DNA adduct levels in WBCs from 43 patets with various types of solid tumours treated with cisplain at a dose of 70-80 mg m-2. Preliminary results indicate that the coefficient of variation of the DNA adduct levels at 1 h post infusion is only 27% with a less than 6-fold range (Ma et al., 1994b) . In our opinion, use of the outlined optimised metho reduces the contribution of assay variation to the inter-patient variability in DNA adduct levels in WBCs.
